v3.26.1
Segment reporting (Details 3)
₨ in Millions, $ in Millions
 12 Months Ended
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
INR (₨)
Mar. 31, 2024
INR (₨)
Disclosure Of Operating Segment [Line Items]        
Revenues ₨ 335,933 [1] $ 3,580 ₨ 325,535 [1] ₨ 279,164 [1]
Pharmaceutical Services and Active Ingredient [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 34,773   33,846 29,801
Pharmaceutical Services and Active Ingredient [Member] | Cardiovascular [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 5,227   7,060 6,915
Pharmaceutical Services and Active Ingredient [Member] | Oncology [member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 5,176   3,398 3,558
Pharmaceutical Services and Active Ingredient [Member] | Nervous System [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 4,087   3,722 2,907
Pharmaceutical Services and Active Ingredient [Member] | Pain Management [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 3,930   3,668 4,221
Pharmaceutical Services and Active Ingredient [Member] | Diabetology [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 1,808   2,039 1,609
Pharmaceutical Services and Active Ingredient [Member] | Hematology [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 1,753   2,458 646
Pharmaceutical Services and Active Ingredient [Member] | Anti-Infective [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 1,739   1,677 1,456
Pharmaceutical Services and Active Ingredient [Member] | Gastrointestinal [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 919   1,220 1,108
Pharmaceutical Services and Active Ingredient [Member] | Dermatology [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 561   742 862
Pharmaceutical Services and Active Ingredient [Member] | Respiratory [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 541   667 899
Pharmaceutical Services and Active Ingredient [Member] | Genitourinary [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues 475   416 367
Pharmaceutical Services and Active Ingredient [Member] | Others [Member]        
Disclosure Of Operating Segment [Line Items]        
Revenues ₨ 8,557   ₨ 6,779 ₨ 5,253
[1] Revenues for the year ended March 31, 2026 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, of Rs.7,270 (as compared to Rs.9,389 and Rs.10,707 for the years ended March 31, 2025 and 2024, respectively) and from the PSAI segment to the Others segment of Rs.0 (as compared to Rs.0 and Rs.72 for the years ended March 31, 2025 and 2024, respectively)